Mylan
Mylan’s Morgantown plant receives FDA warning letter
November 21, 2018Research and Development Mylan, pharma
Generic drugmaker Mylan has received a warning letter from the FDA over concerns surrounding the firm’s manufacturing plant in West …
MHRA to extend EpiPen expiry dates to tackle shortages
October 18, 2018Manufacturing and Production, Sales and Marketing ALK+, Denmark, Mylan, UK, alk, epipen
The British government has extended the expiry date on epinephrine pens amid a shortage in the UK. The Danish pharmaceutical …
EU approval for Mylan and Fujifilm’s Humira biosimilar
September 21, 2018Medical Communications, Sales and Marketing EU, Europe, Humira, Mylan, biosimilar, pharma
The European Commission has approved its fifth biosimilar of the world’s best-selling drug, Abbvie’s Humira (adalimumab), granting marketing authorisation to …
FDA approves first-ever generic EpiPen versions, courtesy of Teva
August 17, 2018Medical Communications, Sales and Marketing FDA, Mylan, Teva, US, epipen, pharma
The FDA has announced the approval of the first generic versions of Mylan’s EpiPen and EpiPen Jr epinephrine auto-injectors as …
US court overturns Allergan’s controversial attempts to avoid Restasis patent review
July 23, 2018Sales and Marketing Allergan, Mylan, Restasis, US, dry eye, pharma
The US Court of Appeals for the Federal Circuit has seen fit to authorise a US Patent and Trademark Office …
AbbVie and Mylan reach US marketing agreement for Humira biosimilar
July 18, 2018Research and Development, Sales and Marketing AbbVie, Humira, Mylan, US, pharma
AbbVie and Mylan have announced that they have both signed a licensing agreement for the former’s proposed biosimilar version of …
Insider Interview: Biosimilars to balance the books
July 9, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Mylan, bisoimilars, multiple sclerosis
Jean-Yves Brault, Country Manager at Mylan UK, discusses how biosimilars are going to play an important role in driving down …
Dr Reddy’s just-approved opioid dependence generic blocked over US patent dispute
June 18, 2018Sales and Marketing Dr Reddy's, FDA, Mylan, US, opioid crisis, opioid dependence, opioids, suboxone
Dr Reddy’s Laboratories has taken two steps forward an one step back after its generic version of Suboxone Film (buprenorphine/naloxone) …
FDA knocks back Mylan’s Advair generic for second time
June 14, 2018Sales and Marketing Advair, FDA, GSK, Mylan, pharma
The FDA has rejected Mylan’s generic version of GlaxoSmithKline’s Advair for the second time following its knockback last year, citing …
Mylan lands biosimilar sucker punch to Amgen’s blockbuster
June 6, 2018Research and Development, Sales and Marketing Amgen, Biocon, Mylan, Neulasta
Mylan and Biocon have received FDA approval for their biosimilar to Amgen’s Neulasta (pegfilgrastim), setting the companies on track to …
Top Ten most popular articles on Pharmafile.com this week
April 20, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, EMA, GW Pharma, J&J, JJ, MHRA, Mylan, Novartis, Sanofi, Shire, Takeda, biotech, drugs, epipen, keytruda, pharma, pharmaceutical
It’s the end of another week and there’s really been one story that has dominated the headlines – Takeda’s potential …
EpiPen shortage hits UK and Canada hard, but not US
April 18, 2018Research and Development, Sales and Marketing Mylan, Pfizer, biotech, drugs, epipen, pharma, pharmaceutical
Manufacturing issues at the single Pfizer plant that produces the EpiPen epinephrine injector has caused serious shortages in the UK …
Top Ten most popular articles on Pharmafile.com this week
April 13, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Cancer, Humira, Mylan, Novartis, Shire, Takeda, Teva, acquisition, cystic fibrosis, hepatitis C, pharma, top ten
It’s Friday the 13th, but that doesn’t change a strong showing from the industry this week as it continued to …
Mylan looks to hit Teva where it hurts, eyeing slow-release MS treatment
April 11, 2018Research and Development, Sales and Marketing Copaxone, Mapi Pharma, Mylan, Teva, biotech, drugs, pharma, pharmaceutical
Mylan has taken several steps recently that seem intended to hit sales of its big rivals on their key products, …
Top Ten most popular articles on Pharmafile.com this week
March 2, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Alzheimer's, AstraZeneca, Botox, Celgene, EMA, FDA, Merck, Mylan, Pfizer, Roche, Takeda, ipsen, vaccines
We’re already into March and, trying to put a bad start to the year behind them on Alzheimer’s research, the …
